Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol
- PMID: 2439812
Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol
Abstract
Models describing the time course of effects (pharmacodynamic models) of various beta blockers in man are used to explain the long duration of action of bopindolol. No matter what effect is used [reduction in exercise heart rate (RER) or isoproterenol dose ratio (DR)] human data show clearly that bopindolol is very potent compared to other beta blockers such as atenolol, metoprolol, pindolol, practolol, and propranolol. In pharmacokinetic terms, however, these drugs show no pronounced difference in their elimination half-life (ranging between 4 and 8 h). Also the site of action of the therapeutic effects (beta 1 receptors) is obviously identical for all beta blockers. Furthermore, there is no evidence to suggest that bopindolol (the prodrug) or hydrolyzed bopindolol (the active substance) is further metabolized to a slowly eliminated active metabolite. Thus, drug disposition provides no argument to explain the long-lasting effects of bopindolol as compared other beta blockers. The long duration of action of bopindolol seems to reflect an usually flat plasma concentration-response curve.
Similar articles
-
Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.Drugs. 1991 Jan;41(1):130-49. doi: 10.2165/00003495-199141010-00010. Drugs. 1991. PMID: 1706984 Review.
-
Beta-blocking action of bopindolol, a new beta-blocker, and its active metabolites in open chest dogs.Arch Int Pharmacodyn Ther. 1993 May-Jun;323:5-15. Arch Int Pharmacodyn Ther. 1993. PMID: 7902696
-
Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.Arzneimittelforschung. 1989 Apr;39(4):454-7. Arzneimittelforschung. 1989. PMID: 2568836
-
[Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].Herz. 1982 Jun;7(3):168-78. Herz. 1982. PMID: 6124492 German.
-
Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance.Clin Physiol Biochem. 1990;8 Suppl 2:28-34. Clin Physiol Biochem. 1990. PMID: 1982759 Review.
Cited by
-
Population pharmacokinetic analysis of bisoprolol.Clin Pharmacokinet. 1989 Jul;17(1):53-63. doi: 10.2165/00003088-198917010-00005. Clin Pharmacokinet. 1989. PMID: 2568209 Clinical Trial.
-
Kinetic-effect models and their applications.Pharm Res. 1987 Apr;4(2):86-91. doi: 10.1023/a:1016402616081. Pharm Res. 1987. PMID: 3334411 Review.
-
Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.Drugs. 1991 Jan;41(1):130-49. doi: 10.2165/00003495-199141010-00010. Drugs. 1991. PMID: 1706984 Review.